On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosimilar), which is currently carrying out its global development plan, has enrolled its first two healthy subjects in New Zealand. This is the first clinical study of a bevacizumab biosimilar to be conducted overseas by a Chinese company. At present, the clinical study is proceeding as planned, with the phase I final report expected to be completed in February 2017.